BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30298320)

  • 21. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ.
    Wong SM; King T; Boileau JF; Barry WT; Golshan M
    Ann Surg Oncol; 2017 Sep; 24(9):2509-2517. PubMed ID: 28455673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
    Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
    Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Male breast cancer: prognostic factors, diagnosis and treatment: a multi-institutional survey of 95 cases].
    Oger AS; Boukerrou M; Cutuli B; Campion L; Rousseau E; Bussières E; Raro P; Classe JM
    Gynecol Obstet Fertil; 2015 Apr; 43(4):290-6. PubMed ID: 25818033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
    Wei JL; Zhang JX; Fu DY
    World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic characteristics of male breast cancer: a report of 21 cases in radiotherapy center of hamedan, iran.
    Sedighi A; Hamed EA; Mohammadian K; Behnood S; Kalaghchi B
    Asian Pac J Cancer Prev; 2013; 14(12):7381-3. PubMed ID: 24460307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
    Yoon TI; Hwang UK; Kim ET; Lee S; Sohn G; Ko BS; Lee JW; Son BH; Kim S; Ahn SH; Kim HJ
    Breast Cancer Res Treat; 2017 Sep; 165(2):311-320. PubMed ID: 28601930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943-2013.
    Gregersen PA; Olsen MH; Urbak SF; Funding M; Dalton SO; Overgaard J; Alsner J
    JAMA Netw Open; 2020 Oct; 3(10):e2022126. PubMed ID: 33090227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of internal mammary node irradiation on long-term outcome and contralateral breast cancer incidence in node-negative breast cancer patients.
    Courdi A; Chamorey E; Ferrero JM; Hannoun-Lévi JM
    Radiother Oncol; 2013 Aug; 108(2):259-65. PubMed ID: 23891092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series.
    Masci G; Caruso M; Caruso F; Salvini P; Carnaghi C; Giordano L; Miserocchi V; Losurdo A; Zuradelli M; Torrisi R; Di Tommaso L; Tinterri C; Testori A; Garcia-Etienne CA; Gatzemeier W; Santoro A
    Oncologist; 2015 Jun; 20(6):586-92. PubMed ID: 25948676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
    Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
    Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
    Chia S; Norris B; Speers C; Cheang M; Gilks B; Gown AM; Huntsman D; Olivotto IA; Nielsen TO; Gelmon K
    J Clin Oncol; 2008 Dec; 26(35):5697-704. PubMed ID: 19001334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
    Altman AM; Kizy S; Yuan J; Denbo JW; Jensen EH; Hui JYC; Tuttle TM; Marmor S
    Ann Surg Oncol; 2018 Aug; 25(8):2296-2302. PubMed ID: 29907942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
    Parsons BM; Uprety D; Smith AL; Borgert AJ; Dietrich LL
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1311-1320. PubMed ID: 30442732
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of family history of breast cancer on tumour characteristics, treatment, risk of second cancer and survival among men with breast cancer.
    Bouchardy C; Rapiti E; Fioretta G; Schubert H; Chappuis P; Vlastos G; Benhamou S
    Swiss Med Wkly; 2013; 143():w13879. PubMed ID: 24222557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Primary Tumor Surgery in Stage IV Male Breast Cancer.
    Muzaffar M; Kachare S; Vohra N
    Clin Breast Cancer; 2017 Jun; 17(3):e143-e149. PubMed ID: 27998656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
    Mook S; Schmidt MK; Rutgers EJ; van de Velde AO; Visser O; Rutgers SM; Armstrong N; van't Veer LJ; Ravdin PM
    Lancet Oncol; 2009 Nov; 10(11):1070-6. PubMed ID: 19801202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second cancer incidence and risk factors in patients with salivary gland cancers.
    Kwon M; Lee JI; Roh JL; Cho KJ; Choe J; Choi SH; Nam SY; Kim SY
    JAMA Otolaryngol Head Neck Surg; 2014 Feb; 140(2):118-23. PubMed ID: 24370632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
    Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
    Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
    Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.